Tinostamustine Now Enrolling in GBM AGILE, a Registrational-Intent Phase 2/3 Adaptive Platform Trial for Patients with Glioblastoma LARKSPUR, Calif. and STAMFORD, CT, April 8, 2026 /PRNewswire/ – The Global Coalition for Adaptive Research (GCAR) and Purdue Pharma L.P....
Data reveals positive preliminary results for investigational agent tinostamustine as a potential first-in-class treatment for glioblastoma. Stamford, Conn. November 19, 2025 – Purdue Pharma L.P. (“Purdue”) announced positive preliminary results from a Phase 1 study...
STAMFORD, Conn. – November 14, 2025 – The United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) today indicated it will approve the Chapter 11 Plan of Reorganization (The “Plan”) for Purdue Pharma L.P. (“Purdue”). The Plan,...
This is another recognition in a series of recent milestones for the potential first-in-class investigational drug, including acceptance into the GBM AGILE adaptive clinical trial Stamford, Conn., Nov. 10, 2025 – Purdue Pharma L.P. (“Purdue”) today announced that...
Stamford, Conn. – Oct. 21, 2025 – Purdue Pharma L.P. (“Purdue”) today announced that its Chapter 11 Plan of Reorganization (“Plan”) received support from more than 99% of voting creditors, based on preliminary voting results. The votes were calculated by Kroll,...
The results, published in the Journal of Clinical Pharmacology, support the nalmefene auto-injector as an important treatment option to support emergency opioid overdose reversal STAMFORD, Conn., Sept. 29, 2025 – A pharmacodynamic study sponsored by Purdue Pharma...
Please read carefully the Purdue Pharma L.P. Privacy Policy (the “Privacy Policy”), which is part of the Purdue Pharma L.P. Terms and Conditions, before you access, download, or otherwise use any of our websites, related other parties’ websites, mobile applications, or any electronic service (collectively, the “Service”). This Privacy Policy describes the information collected through Your use of the Service, how we use it, how we share it, how we protect it, and the choices You can make about Your information.
